Diabetes Professional Care 2018 (DPC2018) is set to become the biggest yetwith a record-breaking attendance expected, leading to the event being described as a “force for good”.
More than 6,500 delegates have pre-registered, with 4,000 predicted to attend – topping last year’s previous record of3,235 delegates and placing it firmly as the UK’s best-attended event for healthcare professionals working in diabetes.
DPC2018 is the UK’s only national, free-to-attend and CPD-accredited conference for those involved in the prevention, treatment and management of diabetes, and its related conditions.
The results of the eagerly-anticipated DECLARE study into cardiovascular disease and type 2 diabetes was shared for the first time in the UK at Diabetes Professional Care (DPC2018).
The research involved 17,000 people and showed how the drug Forxiga (dapagliflozin) reduced hospitalisation for heart failure or cardiovascular (CV) death with no increase in major CV events versus placebo in a broad population with type 2 diabetes.
The session called Cardiovascular outcomes with SGLT2 inhibitors in type 2 diabetes – update from AHA conference took place on Wednesday, November 14, between 3.15pm and 3.45pm.